Literature DB >> 14526311

Prenatal cystic fibrosis screening in Mexican Americans: an economic analysis.

Nora M Doyle1, Michael O Gardner.   

Abstract

OBJECTIVE: We evaluated the cost benefit of cystic fibrosis screening in Mexican American gravid women. STUDY
DESIGN: With the use of decisions analysis techniques, a cost-benefit analysis was performed. Baseline assumptions were based on published references. Sensitivity analyses were performed.
RESULTS: Under the baseline assumptions, screening was not cost beneficial. Threshold analysis showed that, if the test was priced under 53.00 dollars, screening became cost beneficial. Sensitivity analysis demonstrated that lower acceptance rates of amniocentesis or termination made the screening strategy less attractive. If the test sensitivity was raised to 90%, which required testing of >60 mutations, the cost of screening would need to be <100.00 dollars for the program to be cost beneficial.
CONCLUSION: Cystic fibrosis screening is not cost beneficial in Mexican American women over a wide range of assumptions. This is principally due to the poor sensitivity of the test in this population. Cultural factors, such as lower acceptance of amniocentesis and pregnancy termination of affected fetuses, further lower the cost-benefit ratio of screening.

Entities:  

Mesh:

Year:  2003        PMID: 14526311     DOI: 10.1067/s0002-9378(03)00717-8

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  2 in total

Review 1.  Evaluating Cost-effectiveness of Interventions That Affect Fertility and Childbearing: How Health Effects Are Measured Matters.

Authors:  Jeremy D Goldhaber-Fiebert; Margaret L Brandeau
Journal:  Med Decis Making       Date:  2015-04-29       Impact factor: 2.749

2.  Cost-effectiveness of the CFTR gene-sequencing test for asymptomatic carriers in the Colombian population

Authors:  Ernesto Andrade; Jorge Díaz
Journal:  Biomedica       Date:  2020-06-15       Impact factor: 0.935

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.